The Centers for Medicare and Medicaid Services may be planning to ease aspects of its recently-proposed decision that Medicare will only cover amyloid-directed monoclonal antibody drugs for Alzheimer’s disease in the context of a CMS-approved randomized clinical trial.
A final version of the Medicare national coverage determination for the drugs is due by 11 April. CMS has been...







